PMID- 19120337
OWN - NLM
STAT- MEDLINE
DCOM- 20090422
LR  - 20151119
IS  - 1365-2133 (Electronic)
IS  - 0007-0963 (Linking)
VI  - 160
IP  - 3
DP  - 2009 Mar
TI  - First experience with enteric-coated mycophenolate sodium (Myfortic) in severe 
      recalcitrant adult atopic dermatitis: an open label study.
PG  - 687-91
LID - 10.1111/j.1365-2133.2008.08978.x [doi]
AB  - BACKGROUND: Severe atopic dermatitis (AD) is often treated successfully with oral 
      immunosuppressive drugs such as cyclosporin (CsA) or oral corticosteroids. 
      However, some patients develop adverse effects or are unresponsive to these 
      first-choice oral immunosuppressive drugs. OBJECTIVES: To evaluate whether 
      enteric-coated mycophenolate sodium (EC-MPS) is an effective treatment in 
      patients with severe, recalcitrant AD. METHODS: Ten patients with severe, 
      recalcitrant AD were treated with EC-MPS 720 mg twice daily for 6 months. All 
      patients had to discontinue other oral immunosuppressive drugs due to adverse 
      effects (n = 8) or nonresponsiveness (n = 2). Disease activity was monitored 
      using the Severity Scoring of Atopic Dermatitis (modified SCORAD) index and the 
      Leicester Sign Score (LSS). Additionally, the level of serum thymus and 
      activation-regulated cytokine (TARC) was measured. During treatment, safety 
      laboratory examination was performed. Total serum immunoglobulin E (IgE) was 
      followed during treatment. Use of topical corticosteroids was recorded before and 
      during treatment. RESULTS: Compared with baseline, the mean scores for disease 
      activity significantly decreased during treatment with EC-MPS [modified SCORAD (P 
      = 0.04), LSS severity (P = 0.01), LSS extent (P = 0.01)]. In addition, serum TARC 
      levels and total serum IgE levels significantly decreased after treatment 
      compared with before (P = 0.03; P = 0.05). Disease activity decreased after 
      approximately 2 months of treatment and stabilized during the 6-month treatment 
      period. No differences in the amount of topical corticosteroids used in the 6 
      months prior to treatment compared with the 6-month treatment period were found 
      (P = 0.4). None of the patients discontinued use of EC-MPS and only mild adverse 
      effects were seen. CONCLUSIONS: In this study EC-MPS at a dose of 720 mg twice 
      daily for 6 months has proven to be an effective and well-tolerated treatment for 
      patients with severe, recalcitrant AD.
FAU - van Velsen, S G A
AU  - van Velsen SG
AD  - Department of Dermatology and Allergology, University Medical Centre Utrecht, 
      G02.124, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. 
      s.g.a.vanvelsen@umcutrecht.nl
FAU - Haeck, I M
AU  - Haeck IM
FAU - Bruijnzeel-Koomen, C A F M
AU  - Bruijnzeel-Koomen CA
FAU - de Bruin-Weller, M S
AU  - de Bruin-Weller MS
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20081211
PL  - England
TA  - Br J Dermatol
JT  - The British journal of dermatology
JID - 0004041
RN  - 0 (Biomarkers)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Tablets, Enteric-Coated)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - HU9DX48N0T (Mycophenolic Acid)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/blood
MH  - Dermatitis, Atopic/*drug therapy/immunology
MH  - Female
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Immunosuppressive Agents/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Mycophenolic Acid/adverse effects/*therapeutic use
MH  - Severity of Illness Index
MH  - Tablets, Enteric-Coated
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2009/01/06 09:00
MHDA- 2009/04/23 09:00
CRDT- 2009/01/06 09:00
PHST- 2009/01/06 09:00 [entrez]
PHST- 2009/01/06 09:00 [pubmed]
PHST- 2009/04/23 09:00 [medline]
AID - BJD8978 [pii]
AID - 10.1111/j.1365-2133.2008.08978.x [doi]
PST - ppublish
SO  - Br J Dermatol. 2009 Mar;160(3):687-91. doi: 10.1111/j.1365-2133.2008.08978.x. 
      Epub 2008 Dec 11.